TrialClinical drug investigation2026

Cost-Effectiveness Analysis of PI3K Inhibitors for Relapsed or Refractory Follicular Lymphoma in China: A Comparison Between Linperlisib and Duvelisib.

Xuefei Bai et al.PubMed ↗Publisher ↗

No numbers read from the abstract.